See more : Advanced Connection Technology Inc. (3492.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Better Therapeutics, Inc. (BTTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Better Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- EMBASSY OFFICE PAR (EMBASSY-RR.NS) Income Statement Analysis – Financial Results
- Getac Holdings Corporation (3005.TW) Income Statement Analysis – Financial Results
- Microchip Technology Incorporated (MCHP) Income Statement Analysis – Financial Results
- CTEEP – Companhia de Transmissão de Energia Elétrica Paulista S.A. (CTPZY) Income Statement Analysis – Financial Results
- Janus Corporation Limited (JANUSCORP.BO) Income Statement Analysis – Financial Results
Better Therapeutics, Inc. (BTTX)
About Better Therapeutics, Inc.
Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 8.00K | 18.00K |
| Cost of Revenue | 2.73M | 1.62M | 682.00K | 898.00K |
| Gross Profit | -2.73M | -1.62M | -674.00K | -880.00K |
| Gross Profit Ratio | 0.00% | 0.00% | -8,425.00% | -4,888.89% |
| Research & Development | 16.44M | 19.44M | 2.98M | 2.29M |
| General & Administrative | 14.84M | 8.79M | 2.46M | 2.20M |
| Selling & Marketing | 6.98M | 2.34M | 216.00K | 406.00K |
| SG&A | 21.82M | 11.12M | 2.67M | 2.60M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 38.26M | 30.56M | 5.65M | 4.89M |
| Cost & Expenses | 38.26M | 30.56M | 6.33M | 5.79M |
| Interest Income | 1.49K | 185.00 | 100.00 | 11.00 |
| Interest Expense | 1.49M | 185.00K | 100.00K | 11.00K |
| Depreciation & Amortization | 2.73M | 1.62M | 75.00K | 72.00K |
| EBITDA | -38.26M | -30.56M | -6.25M | -5.70M |
| EBITDA Ratio | 0.00% | 0.00% | -78,100.00% | -31,672.22% |
| Operating Income | -38.26M | -30.56M | -6.32M | -5.77M |
| Operating Income Ratio | 0.00% | 0.00% | -79,037.50% | -32,072.22% |
| Total Other Income/Expenses | -1.49M | -9.93M | 89.00K | -11.00K |
| Income Before Tax | -39.75M | -40.49M | -6.23M | -5.78M |
| Income Before Tax Ratio | 0.00% | 0.00% | -77,925.00% | -32,133.33% |
| Income Tax Expense | 7.00K | -153.00K | 153.00K | 11.00K |
| Net Income | -39.76M | -40.34M | -6.39M | -5.80M |
| Net Income Ratio | 0.00% | 0.00% | -79,837.50% | -32,194.44% |
| EPS | -1.69 | -1.71 | -0.85 | -0.25 |
| EPS Diluted | -1.69 | -1.71 | -0.85 | -0.25 |
| Weighted Avg Shares Out | 23.56M | 23.60M | 7.56M | 23.60M |
| Weighted Avg Shares Out (Dil) | 23.56M | 23.60M | 7.56M | 23.60M |
Better Therapeutics: App-Based Therapeutics, Doesn't Look Novel
Better Therapeutics is delivering a cognitive behavioural therapy through a smartphone app. It is targeting traditionally biopharma diseases like diabetes and other cardiometabolic diseases.
2 Falling Knives to Catch
The majority of analysts on Wall Street recommend buying Better Therapeutics Inc. ( BTTX , Financial) and Ginkgo Bioworks Holdings Inc. ( DNA , Financial) shares. That is surprising given these two stocks haven't performed well over the past 52...
Penny Stocks to Buy Right Now? 3 to Watch as the Stock Market Falls
Check these three penny stocks out for your stock market crash watchlist The post Penny Stocks to Buy Right Now? 3 to Watch as the Stock Market Falls appeared first on Penny Stocks to Buy, Picks, News and Information |...
What You Need to Know About Buying Penny Stocks in 2022
Check these tips out for trading penny stocks in 2022 The post What You Need to Know About Buying Penny Stocks in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Penny Stocks With Huge Potential According To 4 Wall Street Analysts
Penny stocks with huge potential according to analysts in 2022. The post Penny Stocks With Huge Potential According To 4 Wall Street Analysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Is Better Therapeutics (BTTX) Stock Up 30% Today?
Better Therapeutics (BTTX) stock is rising higher on heavy trading Monday despite a lack of news from the biotechnology company. The post Why Is Better Therapeutics (BTTX) Stock Up 30% Today?
Best Penny Stocks to Buy Today? 3 to Watch as the Market Drops Again
Here's what you need to know about trading penny stocks today The post Best Penny Stocks to Buy Today? 3 to Watch as the Market Drops Again appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Better Therapeutics Announces Positive Primary Endpoint Data From Pivotal Clinical Trial of BT-001, a Prescription Digital Therapeutic (PDT) for Patients With Uncontrolled Type 2 Diabetes
SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (“Better Therapeutics”, NASDAQ: BTTX), a prescription digital therapeutics company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced primary endpoint data from its pivotal trial of BT-001, a...
Better Therapeutics to Participate in Two Upcoming Investor Events
SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (“Better Therapeutics”; NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, today announced that Kevin Appelbaum, Chief Executive Officer, is scheduled to participate in two...
Better Therapeutics: Pioneering Prescription Digital Therapeutics Platform For Cardiometabolic Diseases
Better Therapeutics has developed a proprietary platform for creating FDA-regulated, software-based solutions for cardiometabolic diseases.
Source: https://incomestatements.info
Category: Stock Reports